Pharmaceutical
-
Steve Saviuk on Valeo Pharma’s TSX Listing and Q1-22 revenues of $4.2 million, up 128% over Q1-21
In a recent InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Revenue Forecasted to Triple as Valeo Benefits from Last Year’s Successes
Valeo Pharma Inc. (CSE: VPH | OTC: VPHIF |FSE: VP2) is a specialty pharmaceutical company and its revenue…
-
Kozak on how Valeo Pharma’s innovative natural health-based product lines are carving their niche in specialty pharmaceuticals
“Valeo is focused on those therapeutic fields where a relatively small number of general practitioners or specialist physicians…
